Literature DB >> 3263897

Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors.

S Miescher1, M Stoeck, L Qiao, C Barras, L Barrelet, V von Fliedner.   

Abstract

The vast majority of tumor infiltrating lymphocytes (TIL) are either CD4+ or CD8+ T-lymphocytes. In order to examine directly the functional capabilities of the individual CD4+ and CD8+ TIL subsets we performed cell sorting of double immunofluorescence-labeled TIL recovered from 15 biopsies by enzyme digestion. These CD4+ and CD8+ TIL subsets were compared with similar subsets of T-lymphocytes from peripheral blood of normal subjects. Both CD4+ and CD8+ TIL showed a reduced clonogenicity as assessed quantitatively by limiting dilution analysis in a microculture system which allows every normal T-lymphocyte to undergo clonal expansion. The reduced clonogenic potential was unequally distributed among the CD4+ and CD8+ subsets with the CD8+ TIL showing a significant reduction of the frequency of proliferating T-lymphocyte precursors compared to the CD4+ TIL (with a median of 1/50 proliferating T-lymphocytes in CD8+ TIL versus a median of 1/11 in CD4+ TIL). The reduced response of CD8+ TIL was not caused by suppressor cells, lack of surface expression of CD2 and CD3 antigens nor of the alpha, beta T-cell receptor, nor by an accumulation of CD8+ cells of large granular lymphocyte morphology. Using low density cultures, the highly purified CD4+ and CD8+ TIL were stimulated either via the T-cell receptor or the CD2-mediated antigen-independent pathway of activation. Whereas CD8+ TIL did not respond to either stimulus the CD4+ TIL showed evidence of responder and nonresponder groups. In addition, we show that the deficient response obtained by triggering CD4+ TIL via the TCR can be restored by activation of the antigen-independent pathway. Finally, a total of 94 clones from four different TIL samples were obtained by limiting dilution and examined for their respective helper and cytolytic capabilities: 57% of the CD4+ TIL clones were able to produce interleukin 2 and 93% of the CD8+ TIL clones demonstrated cytolytic activity mediated by the T-cell receptor complex, indicating that the functional potential of proliferating TIL is intact.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263897

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

3.  Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.

Authors:  R G Uzzo; P Rayman; V Kolenko; P E Clark; M K Cathcart; T Bloom; A C Novick; R M Bukowski; T Hamilton; J H Finke
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 4.  Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives.

Authors:  Patrick Raber; Augusto C Ochoa; Paulo C Rodríguez
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

5.  The expression and cellular distribution of adhesion molecules CD2/LFA-3 and ICAM-1/LFA-1 on mononuclear cells in squamous cell carcinoma of the head and neck.

Authors:  J Kornfehl; C Neuchrist; M C Grasl; K Ehrenberger; D Kraft; O Scheiner
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

6.  Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.

Authors:  Y Shimizu; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

8.  In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

Authors:  M Apiranthitou-Drogari; C Paganin; S Bernasconi; G Losa; A Maneo; N Colombo; A Mantovani; P Allavena
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

Review 10.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Authors:  Paulo C Rodríguez; Augusto C Ochoa
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.